Citations 8

Risk and potential of ChatGPT in scientific publishing

Journal of Inherited Metabolic Disease | August 3, 2023 | Volume: 46 | Issue: 6 | Pages: 1005-1006

10.1002/jimd.12666 | PMID 37534774

Guidelines in the JIMD: Evidence‐based practice for inherited metabolic disease

Journal of Inherited Metabolic Disease | May 9, 2023 | Volume: 46 | Issue: 4 | Pages: 537-538

10.1002/jimd.12620 | PMID 37157107

The doxycycline paradox in primary mitochondrial diseases

Journal of Inherited Metabolic Disease | June 23, 2022 | Volume: 45 | Issue: 4 | Pages: 659-660

10.1002/jimd.12531 | PMID 35734980

Quo vadis now: Beyond genomics to an era of personalised medicine

Journal of Inherited Metabolic Disease | March 1, 2022 | Volume: 45 | Issue: 2 | Pages: 129-131

10.1002/jimd.12487 | PMID 35229313

Expanding the phenotypic spectrum of BCS1L‐related mitochondrial disease

Annals of Clinical and Translational Neurology | October 21, 2021 | Volume: 8 | Issue: 11 | Pages: 2155-2165

10.1002/acn3.51470 | PMID 34662929

AbstractObjectiveTo delineate the full phenotypic spectrum of BCS1L‐related disease, provide better understanding of the genotype–phenotype correlations and identify reliable prognostic disease markers.MethodsWe performed a retrospective multinational cohort study of previously unpublished patients followed in 15 centres from 10 countries. Patients with confirmed biallelic pathogenic BCS1L variants were considered eligible. Clinical, laboratory, neuroimaging and genetic data were analysed. Patients were stratified into different groups based on the age of disease onset, whether homozygous or compound heterozygous for the c.232A>G (p.Ser78Gly) variant, and those with other pathogenic BCS1L variants.ResultsThirty‐three patients were included. We found that growth failure, lactic acidosis, tubulopathy, hepatopathy and early death were more frequent in those with disease onset within the first month of life. In those with onset after 1 month, neurological features including movement disorders and seizures were more frequent. Novel phenotypes, particularly involving movement disorder, were identified in this group. The presence of the c.232A>G (p.Ser78Gly) variant was associated with significantly worse survival and exclusively found in those with disease onset within the first month of life, whilst other pathogenic BCS1L variants were more frequent in those with later symptom onset.InterpretationThe phenotypic spectrum of BCS1L‐related disease comprises a continuum of clinical features rather than a set of separate syndromic clinical identities. Age of onset defines BCS1L‐related disease clinically and early presentation is associated with poor prognosis. Genotype correlates with phenotype in the presence of the c.232A>G (p.Ser78Gly) variant.
Newborn screening: To WES or not to WES, that is the question

Journal of Inherited Metabolic Disease | August 26, 2020 | Volume: 43 | Issue: 5 | Pages: 904-905

10.1002/jimd.12303 | PMID 32844432

Peer review fraud—it's not big and it's not clever

Journal of Inherited Metabolic Disease | December 11, 2015 | Volume: 39 | Issue: 1 | Pages: 1-2

10.1007/s10545-015-9905-x | PMID 26660661

Quo vadis: the re‐definition of “inborn metabolic diseases”

Journal of Inherited Metabolic Disease | September 29, 2015 | Volume: 38 | Issue: 6 | Pages: 1003-1006

10.1007/s10545-015-9893-x | PMID 26420281